Evidence map›Paper›PMID 41393741›Full record

ArticleCureus2025

Rapid Endocrine Remission After ZAP-X Gyroscopic Radiosurgery for Cushing's Disease: A Case Report.

Alper Kahvecioglu, Selin Tekin, Seda Hanife Oguz, Mustafa Berker, Selcuk Dagdelen, Gozde Yazici

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alper KahveciogluRadiation Oncology, Hacettepe University Faculty of Medicine, Ankara, TUR.
Selin TekinEndocrinology, Hacettepe University Faculty of Medicine, Ankara, TUR.
Seda Hanife OguzEndocrinology, Hacettepe University Faculty of Medicine, Ankara, TUR.
Mustafa BerkerNeurosurgery, Hacettepe University Faculty of Medicine, Ankara, TUR.
Selcuk DagdelenEndocrinology, Hacettepe University Faculty of Medicine, Ankara, TUR.
Gozde YaziciRadiation Oncology, Hacettepe University Faculty of Medicine, Ankara, TUR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cushing's disease is a rare but potentially life-threatening disorder caused by excessive adrenocorticotropic hormone (ACTH) secretion from a pituitary adenoma. Although transsphenoidal surgery remains the first-line treatment, radiotherapy (RT) can provide effective local and hormonal control in patients with persistent or recurrent disease; however, endocrine remission typically occurs only after several months or even years. To our knowledge, we report the first documented case of an exceptionally rapid hormonal remission following gyroscopic stereotactic radiosurgery (SRS) using the self-shielding ZAP-X system (ZAP Surgical Inc., San Carlos, CA, USA) in a patient with recurrent Cushing's disease. The patient received a single-fraction dose of 25 Gy prescribed to the 57% isodose line. Remarkably, ACTH and cortisol levels normalized within one month after SRS, accompanied by a striking improvement in clinical symptoms and no treatment-related toxicity. This case highlights the potential of the ZAP-X gyroscopic radiosurgery platform to achieve rapid biochemical control in ACTH-secreting pituitary adenomas and suggests that the unique dose distribution characteristics of this novel technology may contribute to accelerated endocrine responses.

Indexed as

cushing’s diseasepituitary adenoma managementradiotherapy (rt)stereotactic ablative radiationstereotactic radio surgery (srs)stereotactic radiosurgery srszap-x radiosurgical system

Identifiers

PMID41393741
PMCPMC12699235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.